Repare Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RPTX Nasdaq 2836 www.reparerx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Repare Therapeutics Inc.

What Makes Repare Therapeutics (RPTX) a New Buy Stock - Mar 11th, 2025 4:00 pm
Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 7th, 2025 9:05 pm
Here's Why We're Watching Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation - Mar 4th, 2025 11:22 am
Repare Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Mar 4th, 2025 11:09 am
Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results - Mar 3rd, 2025 12:05 pm
Repare Therapeutics Chief Medical Officer to Leave - Feb 25th, 2025 6:09 pm
Myriad Genetics (MYGN) Meets Q4 Earnings Estimates - Feb 24th, 2025 11:00 pm
Repare Therapeutics (RPTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Jan 24th, 2025 2:55 pm
Repare Therapeutics (RPTX) Loses -5.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Jan 21st, 2025 2:35 pm
Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions - Jan 9th, 2025 9:05 pm
Top Midday Decliners - Dec 13th, 2024 6:41 pm
Why Is Repare Therapeutics Stock Trading Lower On Friday? - Dec 13th, 2024 5:09 pm
Repare Therapeutics Shares Drop 38% Following Phase 1 Trial Results - Dec 13th, 2024 4:45 pm
Repare Therapeutics eyes Phase III cancer study after Mythic trial success - Dec 13th, 2024 3:28 pm
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - Dec 12th, 2024 9:20 pm
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial - Dec 10th, 2024 9:05 pm
Industry Analysts Just Made A Notable Upgrade To Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts - Nov 13th, 2024 11:49 am
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - Nov 12th, 2024 12:05 pm
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results - Nov 7th, 2024 12:05 pm
Repare Therapeutics’ individualised anaemia management trial shows promise - Oct 24th, 2024 9:57 am